Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: Implications for drug resistance and in vitro drug screening models

Cell Cycle

Volumn 8, Issue 19, 2009, Pages 3208-3217

  Sabisz, Michal ^a   Skladanowski, Andrzej ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Antitumor drug; Cancer stem cell; DNA damage; DNA topoisomerase II; Lung cancer; Senescence

Indexed keywords

AMSACRINE; ATM PROTEIN; ATR PROTEIN; CAFFEINE; ETOPOSIDE; PROTEIN KINASE B; RAZOXANE;

ARTICLE; CANCER STEM CELL; CELL AGING; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DRUG RESISTANCE; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG TUMOR; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR GROWTH;

EID: 70349912085     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.19.9758     Document Type: Article

References (51)

1. D'Amico D, Carbone D, Mitsudomi T, Nau MM, Fedorko J, Russell E, et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992; 7:339-346
2. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999; 59:3761-3767 (Pubitemid 29381884)
3. waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999; 18:4808-4818
4. Roninson IB. Tumor senescence as a determinant of drug response in vivo. Drug Resist Updat 2002; 5:204-208
5. Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA, et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem 2002; 277:35509-35515
6. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 2004; 23:1283-1290 (Pubitemid 38297183)
7. Elmore LW, Di X, Dumur C, Holt SE, Gewirtz DA. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res 2005; 11:2637-2643
8. Roberson RS, Kussick SJ, Vallieres E, Chen SY, Wu DY. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 2005; 65:2795-2803 (Pubitemid 40490082)
9. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8:729-740
10. Gewirtz DA, Holt SE, Elmore LW. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol 2008; 76:947-957
11. INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene 1998; 16:1113-1123
12. Robles SJ, Buehler PW, Negrusz A, Adami GR. Permanent cell cycle arrest in asynchronously proliferating normal human fibroblasts treated with doxorubicin or etoposide but not camptothecin. Biochem Pharmacol 1999; 58:675-685 (Pubitemid 29296889)
13. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426:194-198
14. INK4a contributes to the outcome of cancer therapy. Cell 2002; 109:335-346
15. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002; 62:1876-1883
16. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006; 124:1111-1115
17. Reya T, Morrison SJ, Clarke MF. Stem cells, cancer and cancer stem cells. Nature 2001; 414:105-111
18. Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. Leukemia 2006; 20:385-391 (Pubitemid 43291733)
19. Barnes DJ, Melo JV. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006; 5:2862-2866
20. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood 2006; 107:431-434 (Pubitemid 43076361)
21. Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther 2007;6:1684-1690 (Pubitemid 351590301)
22. Meng A, Wang Y, Van Zant G, Zhou D. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res 2003; 63:5414-5419 (Pubitemid 37139859)
23. Wang Y, Schulte BA, Zhou D. Hematopoietic stem cell senescence and long-term bone marrow injury. Cell Cycle 2006; 5:35-38
24. Aladjem MI, Spike BT, Rodewald LW, Hope TJ, Klemm M, Jaenisch R, et al. ES cells do not activate p53-dependent stress responses and undergo p53- independent apoptosis in response to DNA damage. Curr Biol 1998; 8:145-155 (Pubitemid 28091572)
25. WAF1/CIP1 degradation. Oncogene 2000; 19:3858-3865
26. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67:4827-4833 (Pubitemid 46910191)
27. Bian H, Rosinski JA, Tureci O, Sahin U, Reidhaar- Olson JF, Hilton H, et al. Identification of molecular characteristics of non-small lung cancer (NSCLC). Proc AACR 2003; 44:639.
28. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92:9363-9367
29. Ryu SW, Woo JH, Kim YH, Lee YS, Park JW, Bae YS. Downregulation of protein kinase CKII is associated with cellular senescence. FEBS Lett 2006; 580:988-994
30. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999; 59:4375-4382 (Pubitemid 29418757)
31. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-1101
32. Damelin M, Sun YE, Sodja VB, Bestor TH. Decatenation checkpoint deficiency in stem and progenitor cells. Cancer Cell 2005; 8:479-484 (Pubitemid 41773451)
33. Chuykin IA, Lianguzova MS, Pospelova TV, Pospelov VA. Activation of DNA damage response signaling in mouse embryonic stem cells. Cell Cycle 2008; 7:2922-2928
34. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008; 7:3355-3361
35. Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004; 431:997-1002. (Pubitemid 39434422)
36. Lee J, Kanatsu-Shinohara M, Inoue K, Ogonuki N, Miki H, Toyokuni S, et al. Akt mediates self-renewal division of mouse spermatogonial stem cells. Development 2007; 134:1853-1859 (Pubitemid 46939231)
37. Feng J, Park J, Cron P, Hess D, Hemmings BA. Identification of a PKB/Akt hydrophobic motif Ser- 473 kinase as DNA dependent protein kinase. J Biol Chem 2004; 279:41189-41196 (Pubitemid 39287721)
38. Viniegra JG, Martínez N, Modirassari P, Losa JH, Parada Cobo C, Lobo VJ, et al. Full activation of PKB/ Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem 2005; 280:4029-4036 (Pubitemid 40288566)
39. Caporali S, Levati L, Starace G, Ragone G, Bonmassar E, Alvino E, et al. AKT is activated in an ataxiatelangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol 2008; 74:173-183 (Pubitemid 351872168)
40. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle 2009; 8:1888-1895
41. Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 2009; 8:1896-1900
42. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007; 13:433-442 (Pubitemid 47570021)
43. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004; 167:399-403.
44. Jones DL, Wagers AJ. No place like home: anatomy and function of the stem cell niche. Nat Rev Mol Cell Biol 2008; 9:11-21.
45. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, et al. Identification and characterization of a novel and specific inhibitor of the ataxiatelangiectasia mutated kinase ATM. Cancer Res 2004; 64:9152-9159 (Pubitemid 39665530)
46. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008; 68:2366-2374
47. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317:337.
48. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res 2008; 68:4018-4021
49. Skladanowski A, Bozko P, Sabisz M, Larsen AK. Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy. Cell Cycle 2007; 6:2268-2275 (Pubitemid 47547705)
50. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101:14228-14233
51. - cancer cells are similarly tumorigenic. Cancer Res 2005; 65:6207-6219